Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-009569
Filing Date
2025-05-12
Accepted
2025-05-12 08:00:49
Documents
46
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 745252
2 EX-31.1 ex31-1.htm EX-31.1 17968
3 EX-31.2 ex31-2.htm EX-31.2 18387
4 EX-32.1 ex32-1.htm EX-32.1 7250
5 EX-32.2 ex32-2.htm EX-32.2 7224
  Complete submission text file 0001641172-25-009569.txt   4042415

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE thar-20250331.xsd EX-101.SCH 27321
7 XBRL CALCULATION FILE thar-20250331_cal.xml EX-101.CAL 26890
8 XBRL DEFINITION FILE thar-20250331_def.xml EX-101.DEF 129744
9 XBRL LABEL FILE thar-20250331_lab.xml EX-101.LAB 307376
10 XBRL PRESENTATION FILE thar-20250331_pre.xml EX-101.PRE 238931
48 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 508065
Mailing Address 245 MAIN STREET SUITE 204 CHESTER NJ 07930
Business Address 1200 ROUTE 22 EAST BRIDGEWATER NJ 08807 302-743-2995
Tharimmune, Inc. (Filer) CIK: 0001861657 (see all company filings)

EIN.: 842642541 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41210 | Film No.: 25932669
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)